Israel's Pluri wins NIH contract for drug that could save lives in nuclear event
Company aims for FDA approval so that its novel cell therapy for radiation sickness can be eligible for US Strategic National Stockpile
Source: timesofisrael.com
Page 2 - Nuclear Countermeasures Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Nuclear Countermeasures Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Nuclear Countermeasures Program Today - Breaking & Trending Today
RedHill Biopharma Provides H1/23 Financial Results and Operational Highlights
RHB-107 included in the U.S. Department of Defense-supported ACESO PROTECT multinational platform trial for early COVID-19 outpatient treatment; The...
Source: prnewswire.com
RedHill's RHB-107 Included in U.S. Government-Supported COVID-19 Platform Trial and Cleared for Initiation by FDA
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that RHB-107 (upamostat)3 has been accepted for inclusion in the Austere environments Consortium for Enhanced Sepsis Outcomes' (ACESO) U.S. Government-supported PROTECT multinational platform trial for early COVID-19 outpatient treatment to be conducted in the U.S., Thailand, Ivory Coast and South Africa. The Company also announced that the Phase 2 study, predominantly funde
Source: yahoo.com
NeoImmuneTech Welcomes Two New Members to its Scientific Advisory Board
/PRNewswire/ -- NeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), a clinical-stage T cell-focused biopharmaceutical company, today announces the addition of two...
Source: prnewswire.com
RedHill Announces Additional U.S. Government Funding for Opaganib Nuclear Countermeasure Development
TEL AVIV - RedHill Biopharma Ltd. , a specialty biopharmaceutical company, today announced that opaganib[1] has been awarded a further $1.7 million in U.S. Government funding, via a Small Business...
Source: marketscreener.com